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Heterogeneity has been observed in outcomes of hospitalized patients with coronavirus dis-
ease 2019 (COVID-19). Identification of clinical phenotypes may facilitate tailored therapy
and improve outcomes. The purpose of this study is to identify specific clinical phenotypes
across COVID-19 patients and compare admission characteristics and outcomes.
Methods
This is a retrospective analysis of COVID-19 patients from March 7, 2020 to August 25,
2020 at 14 U.S. hospitals. Ensemble clustering was performed on 33 variables collected
within 72 hours of admission. Principal component analysis was performed to visualize vari-
able contributions to clustering. Multinomial regression models were fit to compare patient
comorbidities across phenotypes. Multivariable models were fit to estimate associations
between phenotype and in-hospital complications and clinical outcomes.
Results
The database included 1,022 hospitalized patients with COVID-19. Three clinical pheno-
types were identified (I, II, III), with 236 [23.1%] patients in phenotype I, 613 [60%] patients
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in phenotype II, and 173 [16.9%] patients in phenotype III. Patients with respiratory comor-
bidities were most commonly phenotype III (p = 0.002), while patients with hematologic,
renal, and cardiac (all p<0.001) comorbidities were most commonly phenotype I. Adjusted
odds of respiratory, renal, hepatic, metabolic (all p<0.001), and hematological (p = 0.02)
complications were highest for phenotype I. Phenotypes I and II were associated with 7.30-
fold (HR:7.30, 95% CI:(3.11–17.17), p<0.001) and 2.57-fold (HR:2.57, 95% CI:(1.10–6.00),
p = 0.03) increases in hazard of death relative to phenotype III.
Conclusion
We identified three clinical COVID-19 phenotypes, reflecting patient populations with differ-
ent comorbidities, complications, and clinical outcomes. Future research is needed to deter-
mine the utility of these phenotypes in clinical practice and trial design.
Introduction
The coronavirus disease 2019 (COVID-19), a disease caused by the severe acute respiratory
syndrome coronavirus-2 (SARS-CoV-2), has infected over 18 million and led to over 700,000
deaths since first appearing in late 2019 [1]. Researchers are rapidly attempting to understand
the natural history of and immune response to COVID-19 [2]. Despite intense research since
the arrival of this novel coronavirus [3], only one pharmaco-therapeutic agent, dexametha-
sone, has been associated with reduced mortality in at-risk individuals [4]. COVID-19 results
in a constellation of symptoms, laboratory derangement, immune dysregulation, and clinical
complications [5].
Emergency department presentation varies widely, suggesting distinct clinical phenotypes
exist and, importantly, it is likely these distinct phenotypes respond differently to treatment.
To illustrate, two early phenotypes of respiratory failure likely exist in COVID-19. A classic
ARDS phenotype exists with poorly compliant lungs and poor gas exchange; however, a phe-
notype with normal lung compliance also exists in COVID-19 and is hypothesized to be driven
by shunting secondary to pulmonary microthrombi [6, 7]. An intricate, multidimensional
view is required to adequately understand the disease and account for the variation in clinical
outcomes. Furthermore, patients could benefit from phenotype-specific medical care, which
may differ from established standards of care.
Despite this need, few studies have characterized COVID-19 clinical phenotypes and evalu-
ated their association with complications and clinical outcomes. The aim of this study was to
characterize clinical phenotypes in COVID-19 according to disease-system factors using elec-
tronic health record (EHR) data pooled from 14 U.S. Midwest hospitals between March 7,
2020 and August 25, 2020.
Materials and methods
Data collection
The data source for this study included EHR reports from 14 U.S. Midwest hospitals and 60
primary care clinics across Minnesota. The healthcare system includes an academic quaternary
center along with community hospitals all capable of providing critical care. Patient and hospi-
tal-level data were available for 7,538 patients with PCR-confirmed COVID-19. Of these, 1,022
required hospital admission and were included in this analysis. The database included all
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comorbidities reported since March 29, 1997 for each patient and prior to their COVID-19
diagnosis. The database also included home medications, laboratory values, clinic visits, social
history, and patient demographics (age, gender, race/ethnicity, language spoken, zip code,
socioeconomic status indicators). Race/ethnicity are self-reported. For each COVID-19 hospi-
talization the database included all laboratory values, vitals, orders, medications, complica-
tions, length of stay, and hospital disposition. State death certificate data was linked with the
database to enable capture of out-of-hospital death. Additionally, the database allowed linkage
across the 14 hospitals, facilitating the tracking of transfers.
The study was approved by all hospitals within the MHealth Fairview system which
includes ethical approval by the University of Minnesota institutional review board. All
patients have the option to opt-out of research upon establishing care within the MHealth
Fairview healthcare system. Data is aggregated through the University of Minnesota’s central-
ized informatics center and de-identified prior to analysis. Data were pooled across different
electronic health records (EHRs) utilizing a unique patient identifier to account for health care
encounters across systems. This study was approved by the University of Minnesota institu-
tional review board (STUDY00001489), which provided a waiver of consent for this study.
Participants
Patient-level data were obtained from the COVID-19 database from March 7, 2020 to August
25, 2020. The inclusion criterion was as follows: PCR-positive COVID-19 test requiring inpa-
tient hospital admission to one of the 14 hospitals providing data. No hospitalized patients
were excluded in this analysis to maximize generalizability. Follow-up data were available for a
minimum of two weeks following admission for all patients.
Clinical variables for phenotyping
We selected 33 variables for clustering based on their association with COVID-19 mortality,
known COVID-19 pathophysiology, and presence in the database (no more than 50% missing-
ness) [8–11]. The following variables were included: age, body mass index (BMI), heart rate,
respiratory rate, oxygen saturation, pulse pressure, systolic blood pressure, total protein, red
cell distribution width, mean corpuscular volume, alkaline phosphatase, calcium, anion gap,
bicarbonate, hematocrit, aspartate aminotransferase, glucose, absolute monocyte count, abso-
lute neutrophil count, absolute lymphocyte count, white blood cell count, platelet, albumin,
bilirubin, international normalized ratio (INR), lactate dehydrogenase, potassium, sodium, D-
dimer, hemoglobin, C-reactive protein (CRP), creatinine, and gamma gap. For each variable
we selected the first recorded value within the first 72 hours of the emergency department
(ED) presentation that ultimately resulted in their hospitalization.
Comorbidities
We selected 68 comorbidities documented for each patient from March 29, 1997 preceding
their COVID-19 hospital admission in their electronic health record (S1 Table). All comorbid-
ities were identified based on ICD-9, ICD-10, or problem list documentation within the elec-
tronic health record. An indicator variable was created for each comorbidity to denote the
presence of the selected ICD-9, ICD-10, or problem list documentation at any time in the
medical record. To facilitate analysis, comorbidities were grouped by organ system into the
following categories: cardiac, respiratory, hematologic, metabolic, renal, hepatic, autoimmune,
cancer, and cerebrovascular disease.
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Complications and clinical outcomes
We selected 30 in-hospital complications measured during each patient’s hospital stay for
COVID-19 categorized into the following systems: cardiovascular, respiratory, hematologic,
renal, hepatic, metabolic, and infectious (S2 Table). If applicable, complications could span
multiple organ system variables. For example, ventilator associated pneumonia was included
in both infectious and respiratory complications. Additional clinical outcomes included hospi-
tal length of stay (LOS), need for intensive care unit (ICU) admission, need for mechanical
ventilation, and mortality. Mortality was defined as any in-hospital or out-of-hospital death
based on death certificate data. All complications and outcomes were followed for a minimum
of 2 weeks following hospital admission.
Statistical analysis
The overall rate of missingness of the 33 variables used for phenotyping, which included the
first vitals and labs recorded for each inpatient within 72 hours of admission, was 19% (range
0% - 50%). We imputed missing values using multivariate imputations by chained equations
implemented with the mice package (v.3.10.0) [12, 13]. Data were log-transformed before
imputing missing values with predictive mean matching. A total of 40 imputed datasets were
generated. The diceR package (v.1.0.0) [14] was used to perform k-means-based consensus
clustering on each imputed dataset using 80% subsamples and 1,000 iterations. We considered
grouping patients into 2–7 phenotypes and determined the optimal number was 3 by evaluat-
ing the consensus cumulative distribution function (CDF) plot, the delta area plot, and the
consensus matrix heatmap. These figures were generated using the consensus clustering results
for each imputed dataset, and all figures were qualitatively similar across datasets. For visuali-
zation purposes, these images are provided for a randomly selected imputed dataset in S1–S4
Figs. The final assignment of each patient into one of the three phenotypes was determined by
majority voting across the 40 consensus clustering results. Principal component analysis
(PCA) was performed on the average covariance matrix to visualize the relationships among
the three phenotypes and assess variable contributions [15].
Continuous variables were summarized using the median and interquartile range (IQR)
and compared across phenotypes using a Kruskal-Wallis test. Categorical characteristics and
outcomes were summarized using counts and proportions and compared across phenotypes
using a Pearson’s chi-squared test or Fisher’s exact test. Multinomial regression models were
fit to further compare patient comorbidities across phenotype classification.
We next evaluated the relationship between phenotype and subsequent outcomes using
both unadjusted and adjusted models. The adjusted models included sex [16, 17], race and eth-
nicity (white, Black, Asian, Hispanic, other, not reported) [18], and Elixhauser Comorbidity
Index [19], since these are known risk factors for the outcomes of interest and were not
included in the clustering analysis. The associations between phenotype and complications,
ICU admission and need for mechanical ventilation, were estimated using logistic regression
models. Mortality was compared across phenotypes using Cox proportional hazard models
and patients were censored at the last date of data collection, August 25, 2020. Hospital length
of stay was compared across phenotypes using negative binomial regression models. The pri-
mary negative binomial model included individuals who died during hospitalization for
whom length of stay was defined as the number of days until death. We performed a sensitivity
analysis to assess the impact of mortality as a competing risk by refitting the length of stay
model after removing the 127 patients who died. Two-sided p-values < 0.05 were considered
statistically significant. P-values were not adjusted for multiple comparisons. Visualizations of
comorbidities, complications, and outcomes by clinical phenotype were performed using the
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circlize package for R [20]. Comorbidities and complications were grouped into separate organ
systems and the prevalence of each complication/comorbidity type was calculated as a percent-
age for each phenotype. All analyses were conducted using R version 3.6.3 [21] and Stata ver-
sion 16.1 (StataCorp).
Results
The database included 1,022 patients requiring hospital admission with COVID-19. Among
these patients, the median age was 62.1 [IQR: 45.9, 75.8] years; 481 [48.6%] male, 412 [40.3%]
required ICU admission. Additionally, 437 [46.7%] were white, 188 [20.1%] were Black, 159
[17.0%] were Asian, 103 [11.0%] were Hispanic, 20 [2.1%] reported other race, and 28 [2.9%]
did not report. Three clinical phenotypes were identified (I, II, III); 236 [23.1%] patients had
phenotype I, 613 [60%] patients had phenotype II, and 173 [16.9%] patients had phenotype III.
Variable contributions to clustering
The first two principal components (PCs) from PCA were used to visualize the relationship
between phenotypes. PC1 and PC2 captured approximately 11% and 9% of the variance in the
clustering variables, respectively. Thirteen components were needed to explain 70% of the var-
iance (S5 Fig). While phenotypes II and III overlay substantially, phenotype I is more clearly
defined in the right-hand side of the score plot of the first two principal components (Fig 1).
Notably, this figure shows that distinctions between phenotypes are primarily driven by varia-
tion in PC1 as opposed to PC2. The variable contributions to PC1 (S6 Fig) demonstrate that
the largest contributors to the variation in PC1 are from lactate dehydrogenase (LDH), abso-
lute neutrophil count, and D-dimer. These variables therefore prominently contribute to sepa-
rating the three phenotypes as shown in the biplot (Fig 2). Univariate tests showed that LDH,
D-dimer, and neutrophil count are highest in phenotype I. Other variables influential to phe-
notype clustering are white cell count (highest in I), C-reactive protein (highest in I), albumin
(highest in III), aspartate aminotransferase (highest in I), bilirubin (highest in I), and oxygen
saturation (highest in III).
Phenotype characteristics
Differences across phenotypes with respect to patient demographics, admission vitals and labs,
complications, comorbidities, and clinical outcomes are presented in Table 1. Patients with
phenotype I were older than patients in phenotypes II and III (67.2 [52.9, 79.0] years vs. 60.9
[45.9, 75.4] and 58.6 [34.8, 71.3] years respectively, p < 0.001). Patients with phenotype III
were more often female than patients with phenotype I or II (57.6% vs. 41.6% and 53.4%,
respectively, p = 0.002). Patients with phenotype I were less likely to be white (38.8% vs. 45.6%
vs. 60.7%, respectively, p = 0.002) and more likely to be non-English speaking (47.9% vs. 39.2%
vs. 23.7%, respectively, p<0.001). There were no statistically significant differences in BMI or
socioeconomic status, as measured using the area deprivation index, between phenotypes
(Table 1). Patients that presented with phenotype III had a more frequent history of smoking,
alcohol abuse, and neutropenia. Patients that presented with phenotype II had a less frequent
history of hepatic disease than phenotypes I or III (Table 1).
When grouping comorbidities by organ system, cardiac (p<0.001), respiratory (p = 0.002),
hematologic (p<0.001), and renal (p<0.001) comorbidities were found to be significantly
associated with phenotype. Cancer, hepatic, autoimmune, cerebrovascular, and metabolic
comorbidities were not significantly associated with phenotype (Table 1, S7 Fig). Based on the
estimated relative risk ratios, patients with renal (RRR 2.35; 95% CI 1.5–3.67; p<0.001), hema-
tologic (RRR 2.64; 95% CI 1.75–3.98; p<0.001), and cardiac comorbidities (RRR 2.65; 95% CI:
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1.68–4.17; p <0.001) were more likely to have phenotype I vs. III (Fig 3). Patients with respira-
tory comorbidities were 0.47 (95% CI: 0.31–0.72; p<0.001) times as likely to have phenotype I
vs. III and 0.74 (95% CI: 0.52–1.04 p = 0.09) times as likely to have phenotype II vs. III (Fig 3).
Association between phenotype and clinical outcomes
Clinical phenotypes I and II were associated with increased odds of respiratory (I: OR: 2.98,
95% CI 1.58–5.59; II: OR: 2.32, 95% CI: 1.29–4.17; p<0.001), renal (I: OR: 7.04, 95% CI 3.11–
15.9; II: OR: 2.57, 95% CI: 1.15–5.74; p<0.001), and metabolic (I: OR: 4.85, 95% CI: 2.78–8.45;
II: OR: 2.57, 95% CI: 1.52–4.34; p<0.001) complications, compared to phenotype III after
adjusting for sex, race, and Elixhauser Comorbidity Index (S3 Table). There was a trend
towards increased odds of hematologic complications among patients with phenotype I (I:
OR: 2.11, 95% CI: 0.99–4.48, p = 0.05) compared to III. Phenotype was associated with hepatic
complications (p<0.001); however, while phenotype I was associated with a 8.35-fold (OR:
8.35, 95% CI: 1.93–36.11, p< 0.001) increase in the odds of hepatic complication, phenotype
II did not differ significantly from phenotype III (OR: 0.56, 95% CI: 0.10–3.09, p = 0.51). This
is not surprising since only 4 individuals in phenotype II and 2 in phenotype III experienced
hepatic complications during hospitalization (Table 1). Phenotype was also significantly asso-
ciated with the rate of infectious complications (p<0.001) for phenotype 1 (OR 2.57, 95% CI
1.57–4.21;<0.001) but not did not reach statistical significance for phenotype 2 (OR 1.51, 95%
CI 0.96–2.38; p = 0.07) (S3 Table and S8 Fig).
Clinical phenotypes differed in odds of ICU admission (p<0.001) and mechanical ventila-
tion (p<0.001), hospital LOS (p<0.001), and risk of mortality (<0.001) on adjusted analysis
which accounted for sex, race, and Elixhauser Comorbidity Index (Table 2, S9 Fig). Control-
ling for these risk factors and compared to phenotype III, phenotypes I and II were associated
with 7.88-fold (OR: 7.88, 95% CI: 4.65–13.37) and 2.32-fold (OR: 2.32, 95% CI: 1.46–3.68)
increases in the odds of ICU admission, respectively. Phenotypes I and II were associated with
25.59-fold (OR: 25.59, 95% CI: 7.69,-85.17) and 7.45-fold (OR: 7.45, 95% CI: 2.27–24.43)
increases in the odds of requiring mechanical ventilation. Phenotypes I and II were associated
with 1.74-fold (IRR: 1.74, 95% CI: 1.45–2.10, p<0.001) and 1.22-fold (IRR: 1.22, 95% CI: 1.05–
1.43, p = 0.01) increases in hospital LOS. Phenotype I was associated with a 7.30-fold (HR:
7.30, 95% CI: 3.11–17.17, p<0.001) increase in risk of mortality, and Phenotype II had a
2.57-fold (HR: 2.57, 95% CI: 1.10–6.00, p = 0.03) increase in the hazard of death compared to
Phenotype 3. We performed a sensitivity analysis to assess the impact of mortality as a compet-
ing risk by fitting the LOS model before and after removing the 127 patients who died. The
estimated effect sizes were similar between these two models (S4 Table). Table 2 includes the
LOS model with only survivors. S4 Table shows the home medications and Day 5 labs of the
three identified phenotypes (S5 Table).
Discussion
This is one of the first studies to report on clinical phenotypes associated with COVID-19. We
identified three clinical phenotypes for patients with COVID-19 on hospital presentation.
Most patients presented with phenotype II, which is associated with a moderate course and an
approximately 10% mortality. A subset of patients presented with the more severe phenotype
I, which is associated with a staggering 27% mortality. Patients with cardiac, hematologic, and
Fig 1. Score plot: PC2 vs. PC1. The principal component scores for PC1 and PC2 are plotted. Each point represents a patient in the dataset. Colors
represent the cluster (phenotype) that the patient was assigned to by consensus clustering. Ellipses around each cluster/phenotype specify 95%
confidence intervals, assuming a bivariate normal distribution. Abbreviations: PC1 (principal component 1); PC2 (principal component 2).
https://doi.org/10.1371/journal.pone.0248956.g001
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renal comorbidities were most likely to be characterized by phenotype I. Surprisingly, respira-
tory comorbidities appeared less related to phenotypes I or II and were most associated with
phenotype III, which had the most indolent course. Despite this indolent course, patients with
phenotype III had the highest rate of readmission which is likely in part due to the high sur-
vival rate. This also suggests patients with pre-existing respiratory comorbidities, while not at
highest risk for mortality, may be at highest risk for long term sequalae following COVID-19.
Patients that presented with phenotype I were most associated with the development of respi-
ratory, hematologic, renal, metabolic, hepatic, and infectious complications. Surprisingly, car-
diovascular complications did not significantly differ between phenotypes.
Elucidating patient risk factors and severe COVID-19 disease markers may allow early
treatment implementation that may improve the patient’s outcome. Multiple studies have doc-
umented COVID-19 risk factors; however, most have done so from a homogenous lens. For
example, a prospective cohort study from New York City identified that the most considerable
risks for hospital admission were age, male sex, heart failure, chronic kidney disease, and high
BMI [22]. A large observational study conducted in the UK reported that increasing age, male
gender, comorbidities such as cardiac disease, chronic lung disease, chronic kidney disease,
and obesity were associated with higher mortality in COVID-19 positive patients admitted to
the hospital.14 A study from China found that increased odds of in-hospital death due to
COVID-19 were associated with older age, higher sequential organ failure assessment (SOFA)
score and D-dimers > 1.0 μg/mL on admission [23]. Another retrospective study reported
that patients with severe COVID-19 disease and diabetes had increased leucocytes, neutrophils
count, and increased C-reactive protein (CRP), D-dimers, fibrinogen levels [24]. A systematic
review and meta-analysis found that the biomarkers associated with increased mortality
include higher CRP, higher D-dimers, increased creatinine, and lower albumin levels [25].
However it is well known that patients do not have a singular natural history of disease. Multi-
ple studies including this study found that only half of patients suffer a primarily respiratory
disease [26, 27]. Patients suffer a constellation of cardiovascular, hematologic, renal, or hepatic
progression of disease following COVID-19. It is likely patient baseline risk factors related to
the virus [28], home medications [16, 29], genetic predisposition [30], race/ethnicity [18], and
other factors predispose patients to one of the various clinical manifestations and natural his-
tory of COVID-19.
Treatment of hospitalized patients should be tailored based on the clinical courses most
likely for a patient given their a priori risk. For example, phenotypes with a higher risk of
thrombotic events, may benefit from more aggressive anticoagulation. Phenotypes more
prone to infectious complications, may benefit from more targeted immunomodulation
instead of broad and systemic steroid therapy. A key first step to evaluate these treatment deci-
sions is to characterize and describe clinical phenotypes requiring hospitalization. In this anal-
ysis we identified three clinical phenotypes for patients that required hospitalization for
COVID-19. Few studies to date have attempted to elucidate clinical phenotypes. One study
attempted to characterize clinical phenotypes at ICU admission using a dataset of 85 critically
ill patients [31]. Similar to our analysis, they identified three distinct clinical phenotypes. Their
Fig 2. PCA biplot: PC2 vs. PC1. The scores (points) and loadings (arrows) of PC1 and PC2 are plotted for each patient and variable in the model. 95%
confidence ellipses for the scores are shown. The biplot facilitates interpretation of the scores and loadings, assigning context to the variables which
prominently contribute to the phenotypes. Abbreviations: PC1 (principal component 1); PC2 (principal component 2); PCA (principal component
analysis); Abs_Nphil_Ct (absolute neutrophil count); LDH (lactate dehydrogenase); CRP (C-reactive protein); WBC (white blood cell count); HCT
(hematocrit); HGB (hemoglobin); Tbili (total bilirubin); RDW (red cell distribution width); AST (aspartate aminotransferase); Alk_phos (alkaline
phosphatase); RR (respiratory rate); CA (calcium); TP (total protein); INR (internal normalized ratio of prothrombin time); CO2 (carbon dioxide); K
(potassium); O2SAT (oxygen saturation); BMI (body mass index); PLT (platelet); PP (pulse pressure); Na (sodium); SBP (systolic blood pressure);
Abs_mono_ct (absolute monocyte count); MCV (mean corpuscular volume).
https://doi.org/10.1371/journal.pone.0248956.g002
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Table 1. Baseline demographics, comorbidities, and clinical outcomes of hospitalized COVID-19 patients with clinical phenotypes I, II, and III.
Phenotype I Phenotype II Phenotype III P-value
N = 236 N = 613 N = 173
Demographics
Age (years) 67.2 (52.9–79.0) 60.9 (45.9–75.4) 58.6 (34.8–71.3) <0.001
Male 132 (58.4%) 277 (46.6%) 72 (42.4%) 0.002
Race / Ethnicity 0.002
White 81 (38.8%) 257 (45.6%) 99 (60.7%)
Black 53 (25.4%) 105 (18.7%) 30 (18.4%)
Asian 39 (18.7%) 101 (17.9%) 19 (11.7%)
Hispanic 26 (12.4%) 66 (11.7%) 11 (6.7%)
Declined 3 (1.4%) 22 (3.9%) 3 (1.8%)
Other 7 (3.3%) 12 (2.1%) 1 (0.6%)
Non-English Speaking 113 (47.9%) 240 (39.2%) 41 (23.7%) <0.001
National ADI 44.5 (25.0–56.0) 43.0 (25.0–56.0) 37.0 (26.0–62.0) 0.76
BMI (kg/m2), mean (SD) 29.5 (8.9) 30.8 (8.2) 30.4 (13.4) 0.21
Smoker 9 (3.8) 44 (7.2) 18 (10.4) 0.03
Alcohol abuse 14 (5.9) 47 (7.7) 28 (16.2) <0.001
Comorbidities
Elixhauser Comorbidity Index 7.0 (4.0–10.0) 5.0 (3.0–9.0) 5.0 (2.0–8.0) <0.001
Cardiac 194 (82.2%) 428 (69.8%) 110 (63.6%) <0.001
Respiratory 55 (23.3%) 198 (32.3%) 68 (39.3%) 0.002
Hematologic 127 (53.8%) 220 (35.9%) 53 (30.6%) <0.001
Metabolic 175 (74.2%) 477 (77.8%) 121 (69.9%) 0.08
Renal 92 (39.0%) 170 (27.7%) 37 (21.4%) <0.001
Hepatic 46 (19.5%) 82 (13.4%) 25 (14.5%) 0.08
Autoimmune 40 (16.9%) 126 (20.6%) 23 (13.3%) 0.07
Cancer 29 (12.3%) 73 (11.9%) 16 (9.2%) 0.58
Cerebrovascular disease 52 (22.0%) 106 (17.3%) 33 (19.1%) 0.28
Blood Type O 72 (42.4%) 158 (39.0%) 39 (37.5%) 0.67
In-hospital Complications
Cardiovascular 16 (6.8%) 46 (7.5%) 13 (7.5%) 0.93
Respiratory 49 (20.8%) 104 (17.0%) 14 (8.1%) 0.002
Hematologic 27 (11.4%) 35 (5.7%) 10 (5.8%) 0.01
Renal 54 (22.9%) 60 (9.8%) 7 (4.0%) <0.001
Metabolic 85 (36.0%) 141 (23.0%) 18 (10.4%) <0.001
Hepatic 21 (8.9%) 4 (0.7%) 2 (1.2%) <0.001
Infectious 76 (32.2%) 134 (21.9%) 27 (15.6%) <0.001
Clinical Outcomes
ICU Admission 158 (66.9%) 220 (35.9%) 34 (19.7%) <0.001
Mechanical Ventilation 98 (41.5%) 88 (14.4%) 4 (2.3%) <0.001
Hospital Readmission 6 (2.5%) 29 (4.7%) 14 (8.1%) 0.03
ECMO 7 (3.0%) 1 (0.2%) 0 (0.0%) <0.001
In- or Out of hospital mortality 63 (26.7%) 57 (9.3%) 7 (4.0%) <0.001
Admission Vitals and Labs Phenotype I Phenotype II Phenotype III P value
Heart rate (mean (SD)) 96.17 (20.82) 93.93 (19.35) 90.16 (22.3) 0.01
Respiratory rate 22.0 (18.0–28.0) 20.0 (18.0–23.0) 18.0 (16.0–20.0) <0.001
Oxygen saturation 94.0 (89.0–97.0) 95.0 (92.0–97.0) 97.0 (95.0–99.0) <0.001
Pulse pressure 55.0 (43.5–70.5) 53.0 (43.0–68.0) 51.0 (40.0–62.0) 0.02
(Continued)
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low mortality cluster which they called cluster 1 was very similar to our phenotype III with a
predominance of females, lower mortality rate, lower D-dimer and CRP levels. Similarly, their
high mortality cluster was predominantly male, with elevated inflammation markers on ICU
presentation. In this study, we not only characterized three clinical phenotypes, but extended
findings outside of the ICU by characterizing the association of comorbidities with clinical
phenotype and the association of clinical phenotypes with in-hospital complication and clini-
cal outcomes.
Phenotype I can be termed the “Adverse phenotype” and was associated with the worst clin-
ical outcomes. Lactate dehydrogenase (LDH), absolute neutrophil count, D-dimer, aspartate
aminotransferase (AST), and C-reactive protein (CRP) were most influential in phenotype I
determination. The strong association of red cell distribution width (RDW) with phenotype I
was interesting. RDW was strongly associated with genetic age which is hypothesized to be a
Table 1. (Continued)
Phenotype I Phenotype II Phenotype III P-value
N = 236 N = 613 N = 173
SBP (mean (SD)) 133.29 (27.14) 132.46 (23.54) 134.10 (26.26) 0.72
Total protein 6.5 (5.9–7.0) 6.7 (6.20–7.2) 6.6 (6.2–7.1) 0.01
Red cell distribution width 14.1 (13.2–15.4) 13.5 (12.9–14.7) 13.5 (12.8–14.6) <0.001
Mean corpuscular volume 90.0 (86.0–94.0) 89.0 (85.0–93.0) 92.0 (88.0–95.3) <0.001
Alkaline phosphatase 88.0 (67.5–129.0) 71.0 (55.5–92.0) 72.0 (58.-88.0) <0.001
Calcium 8.10 (7.6–8.5) 8.30 (8.0–8.7) 8.40 (8.1–8.9) <0.001
Anion gap 9.0 (7.0–12.0) 8.0 (6.0–10.0) 7.0 (6.0–9.0) <0.001
CO2 23.25 (21.0–26.0) 24.0 (22.0–27.0) 25.0 (23.0–27.8) <0.001
Hematocrit 36.40 (32.3–40.2) 37.60 (33.6–41.1) 38.45 (35.7–41.5) <0.001
Aspartate aminotransferase 55.0 (38.0–95.0) 35.0 (24.0–53.0) 29.0 (20.0–44.0) <0.001
Glucose 122.0 (101.0–165.0) 112.0 (96.0–149.5) 104.0 (91.0–126.5) <0.001
Absolute monocyte count 0.40 (0.3–0.8) 0.40 (0.3–0.6) 0.50 (0.3–0.7) <0.001
Platelets 206.0 (160.0–290.0) 190.0 (149.0–243.0) 196.0 (142.5–247.5) 0.01
Albumin 2.40 (2.0–2.7) 2.80 (2.5–3.1) 3.10 (2.8–3.4) <0.001
Bilirubin 0.70 (0.4–1.1) 0.40 (0.3–0.6) 0.40 (0.3–0.6) <0.001
INR 1.11 (1.03–1.28) 1.06 (0.99–1.17) 1.08 (0.98–1.21) 0.001
Lactate dehydrogenase 460.5 (380.0–562.8) 308.0 (249.0–394.0) 231.0 (180.0–293.5) <0.001
Potassium 4.0 (3.6–4.3) 3.80 (3.6–4.2) 3.80 (3.6–4.2) 0.101
Sodium 137.5 (134.0–141.0) 137.0 (135.0–139.0) 138.0 (136.0–140.0) 0.003
D-dimer 3.08 (1.71–5.57) 0.87 (0.59–1.27) 0.60 (0.36–1.05) <0.001
Hemoglobin 11.90 (10.5–13.1) 12.20 (10.7–13.5) 12.40 (11.3–13.7) 0.01
C-reactive protein 157.0 (102.0–244.0) 89.0 (55.0–134.8) 12.0 (5.0–20.0) <0.001
Creatinine 1.06 (0.77–1.62) 0.84 (0.69–1.13) 0.80 (0.68–1.03) <0.001
Absolute neutrophil count 8.05 (5.75–11.42) 4.20 (3.0–6.0) 2.90 (1.8–4.3) <0.001
Absolute lymphocyte count 0.90 (0.6–1.3) 0.90 (0.7–1.3) 1.30 (0.9–1.7) <0.001
WBC 8.74 (5.68–15.42) 4.50 (3.0–6.71) 2.36 (1.31–3.77) <0.001
Gamma Gap 9.80 (7.2–13.2) 5.90 (4.3–7.6) 4.90 (3.9–7.3) <0.001
Table 1 presents summary statistics of patient demographics, comorbidities, in-hospital complications, clinical outcomes, and admission vitals and labs for each clinical
phenotype (I, II, III). Admissions vitals and labs were used to create the phenotypes. Categorical variables are presented as count (%). Continuous variables are
presented as median (interquartile range) unless otherwise specified.
Abbreviations: ADI, area deprivation index; BMI, body mass index; INR, internal normalized ratio of prothrombin time; ECMO, Extracorporeal membrane
oxygenation; ICU, Intensive Care Unit
https://doi.org/10.1371/journal.pone.0248956.t001
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risk factor in COVID-19 [30]. As people age, variability in red blood cell volumes increases.
Similarly, Gamma Gap, a marker of immunoglobulin levels, was elevated in all three pheno-
types (median > 3.5) [32]. However, patients with clinical phenotype I were noted to have the
largest increase in Gamma Gap. In this scenario elevated Gamma Gap was likely an indicator
of systemic inflammation and has been associated in other inflammatory disease processes
with prognosis. Other groups have previously reported on the importance of the Absolute
Neutrophil to Absolute Lymphocyte count, here we noted that ANC/ALC was lowest for phe-
notype III and highest for phenotype I, in line with previous reports. Patients with cardiac,
hematologic, and renal comorbidities were most prone to develop phenotype I. Phenotype I
was associated with numerous complications (hematologic, hepatic, metabolic, renal, respira-
tory, and infectious) when compared to other phenotypes. It is interesting to note despite a
higher rate of baseline cardiac comorbidities phenotype I was not associated with increased
cardiac complications. Beyond the pathophysiologic differences, it is important to note the
higher proportion of non-White and non-English speaking patients in phenotype I. Moreover,
Fig 3. Relative risk ratio of comorbidities to clinical phenotypes. Relative Risk ratios of comorbidities of phenotypes I and II compared to the reference group
phenotype III.
https://doi.org/10.1371/journal.pone.0248956.g003
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socioeconomic status was similar across all phenotypes, which has been proposed to be a
driver of disparate outcomes in healthcare. These findings are consistent with a recent study
conducted across this populations of patients which found COVID-19 severity to be associated
with minority populations and non-English speaking patients, independent of socioeconomic
status. Given race/ethnicity and primary language spoken are social constructs and traits,
respectively, which are not biologically grounded; these results require further investigation as
to why these populations are at higher risk of developing phenotype I through mediation anal-
ysis of external factors (as opposed to these populations being an isolated cause of developing
an unfavorable phenotype).
Phenotype III was associated with the best clinical outcomes and can be termed the “Favor-
able Phenotype”. Surprisingly, patients with phenotype III had a very high rate of respiratory
comorbidities and the best clinical outcomes. What is most surprising is despite the lowest
complication rate and mortality, this phenotype was associated with a greater than 10% rate of
hospital readmission. Long-term sequelae from the critically ill remains an important target
for patient centered improvements in care given the increasing loss of functional status among
ICU patients predating the pandemic. It is possible that patients pre-existing respiratory
comorbidities predisposed them to longer term sequelae which may have resulted in this read-
mission rate, although additional studies are needed to better elucidate these findings, specifi-
cally controlling for differences in survival. Patients with respiratory comorbidities such as
asthma and COPD routinely use medications which may be protective in SARS-CoV-2 patho-
genesis which may explain this protective effect. For example, our group has previously identi-
fied reduced mortality in COVID-19 for patients with asthma treated with beta2-agonists [16].
Patients with phenotype III were more likely to use inhaled steroids, nasal fluticasone, albute-
rol, and antihistamines.
Clinical phenotypes are critical during a pandemic when time and resources are scarce.
Phenotypes not only enable the identification of risk factors; they also provide essential insight
Table 2. Association of clinical phenotype with clinical outcome.
In- and Out- of Hospital Mortality (Cox PH) HR 95% CI P value
Mortality <0.001 (LR test)
Phenotype I 7.30 3.11–17.17 <0.001
Phenotype II 2.57 1.10–6.00 0.03
Binary Outcomes (Logistic Regression) OR 95% CI P value
ICU Admission <0.001 (LR test)
Phenotype I 7.88 4.65–13.37 <0.001
Phenotype II 2.32 1.46–3.68 <0.001
Mechanical Ventilation <0.001 (LR test)
Phenotype I 25.59 7.69–85.17 <0.001
Phenotype II 7.45 2.27–24.43 <0.001
Count Outcome (Binomial Regression) IRR 95% CI P value
Hospital LOS� <0.001 (LR test)
Phenotype I 1.74 1.45–2.10 <0.001
Phenotype II 1.22 1.05–1.43 0.01
Abbreviations: PH, proportional hazards; HR, hazard ratio; CI, confidence interval; OR, odds ratio; ICU, intensive
care unit; IRR, incidence rate ratio; LOS, length of stay; LR, likelihood ratio.
Reference group for all models is Phenotype III. All models adjusted for sex, race/ethnicity, and Elixhauser
Comorbidity Index.
� LOS model only included patients that survived.
https://doi.org/10.1371/journal.pone.0248956.t002
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towards the high yield follow up investigations. For example, while noting the respiratory asso-
ciations with phenotype III (favorable phenotype) is interesting, the more beneficial take away
includes further investigations towards how these underlying conditions and/or their medica-
tions may mitigate illness severity. Lastly, by phenotyping patients affected by COVID-19; we
set the foundation to begin comparing if these phenotypes are unique to SARS-CoV-2 or if
similarities exist elsewhere.
As the attention paid to personalized medicine accelerates; these studies are just the begin-
ning. Future work will expand upon these phenotypes with the hope that they can assist in 1)
identifying those at risk of poor outcomes, 2) precisely treating each phenotype (which may
not be uniform across all phenotypes), and 3) preventing further complications in those phe-
notypes at higher risk. In addition, a deeper investigation into clinical phenotypes and associ-
ated genomic, transcriptomic, and proteomic is needed. The ability to classify patients into
clinical phenotypes can facilitate the linkage of—omics data to better understand SARS-CoV-2
pathogenesis and natural history. Work is already being done to identify genetic host factors
that may play a role in determining not only susceptibility to the virus, but also the clinical tra-
jectory when infection does occur. Understanding COVID-19 severity, its biomarkers, and
risk factors is paramount during the COVID-19 pandemic.
Our study has several limitations, including that this is a retrospective study and therefore
results may be biased or subject to residual confounding. Second, patients were followed for
variable lengths of time. Patients that were admitted in March 2020 thus had approximately 5
months of follow-up whereas patients admitted in late August had limited time. We accounted
for this by conducting a Cox proportional hazard analysis when analyzing in- and out- of hos-
pital mortality. Additionally, when the data were pulled, only 54 patients (5%) remained hospi-
talized. While most patients developed complications within their first 2 weeks of hospital
admission, it is possible that they may still develop clinical complications which is not reflected
in this analysis. Furthermore, our analysis was completed on hospitalized patients. It is impor-
tant to recognize that our results are restricted to those who required hospitalization. Our data
cannot be extrapolated to those with mild COVID-19 (i.e. not requiring hospitalization).
Conclusion
In this retrospective analysis of patients with COVID-19, three clinical phenotypes were iden-
tified reflecting adverse, moderate, and favorable outcomes. Patients from each phenotype pre-
sented with different comorbidities and developed different complications. Our results suggest
that phenotype-specific medical care of COVID-19 may improve outcomes. Future research is
urgently needed to determine the utility of these phenotypes in clinical practice and trial
design.
Supporting information
S1 Fig. Consensus cumulative distribution functions. Cumulative distribution functions
(CDF) for a randomly selected imputed dataset are shown. A range of phenotypes (2–7) were
considered, and the optimal choice of phenotypes is 3.
(TIF)
S2 Fig. Delta area. The relative change in delta area under the cumulative distribution func-
tion is shown for the range of phenotypes (k = 2–7) for a randomly selected imputed dataset.
The optimal choice of phenotypes is 3. Abbreviations: CDF (cumulative distribution func-
tion).
(TIF)
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S3 Fig. Consensus matrix with 3 clusters. A consensus matrix heatmap is shown for a randomly
selected imputed dataset clustered into 3 phenotypes. The heatmap allows visualization of consen-
sus cluster assignments to evaluate cluster stability. Darker shades of green indicate higher stability.
(TIF)
S4 Fig. Consensus matrix with 4 clusters. A consensus matrix heatmap is shown for a ran-
domly selected imputed dataset clustered into 4 phenotypes. The heatmap allows visualization
of consensus cluster assignments to evaluate cluster stability. Darker shades of green indicate
higher stability. The choice of 4 clusters shows less stability than 3 clusters (see S3 Fig).
(TIF)
S5 Fig. Cumulative proportion of variance explained. The proportion of variance explained
by each principal component is summed over all principal components. For example, PC1 and
PC2 cumulatively explain 20% of the variation in the dataset. Abbreviations: PC1 (principal
component 1); PC2 (principal component 2).
(TIF)
S6 Fig. Contribution of variables to PC1. The contributions of each of the 33 variables used
in the clustering to principal component 1 are shown. The red line marks the expected average
contribution of each variable if the contributions of the variables were uniform across the data-
set. Variables contributing most to the observed pattern in PC1 are D-dimer and albumin.
Abbreviations: PC1 (principal component 1); Abs_Nphil_Ct (absolute neutrophil count);
LDH (lactate dehydrogenase); CRP (C-reactive protein); WBC (white blood cell count); HCT
(hematocrit); HGB (hemoglobin); Tbili (total bilirubin); RDW (red cell distribution width);
AST (aspartate aminotransferase); Alk_phos (alkaline phosphatase); RR (respiratory rate); CA
(calcium); TP (total protein); INR (internal normalized ratio of prothrombin time); CO2 (car-
bon dioxide); K (potassium); O2SAT (oxygen saturation); BMI (body mass index); PLT (plate-
let); PP (pulse pressure); Na (sodium); SBP (systolic blood pressure); Abs_mono_ct (absolute
monocyte count); MCV (mean corpuscular volume).
(TIF)
S7 Fig. Comorbidities by phenotype. Chord diagram illustrates the prevalence of comorbidi-
ties (% observed) for the three clinical phenotypes.
(TIF)
S8 Fig. Complications by phenotype. Chord diagram illustrates the prevalence of complica-
tions (% observed) for the three clinical phenotypes.
(TIF)
S9 Fig. Clinical outcomes by phenotype. Chord diagram illustrates the prevalence of clinical
outcomes (% observed) for the three clinical phenotypes. Abbreviations: ICU (intensive care
unit); Vent (mechanical ventilation); Readmit (readmission to hospital or ICU); ECMO (extra-
corporeal membrane oxygenation).
(TIF)
S1 Table. Categories of comorbidities and ICD 10 codes used.
(PDF)
S2 Table. List of complications contributing to each complication category.
(PDF)
S3 Table. Association of clinical phenotype with in-hospital complications.
(PDF)
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S4 Table.
(PDF)
S5 Table. Home medications and hospital day 5 laboratory values of hospitalized COVID-
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